Evaxion Biotech

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.

Gabrielle Masson Sep 25, 2025 7:00am

concept of computer chip and dollar sign

Merck bags options on Evaxion's AI-designed vaccine candidates

Sep 26, 2024 7:30am

Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders

Aug 9, 2024 8:30am

Sanofi finds new R&D head—Chutes & Ladders

Sep 1, 2023 9:30am

3 more biotechs look to cull, partner assets

Nov 14, 2022 11:40am